Mark Olsen Comment On Regulatory Notice 22-08
Funding is extremely challenging. Additional regulations are not the answer. I deal with "sophisticated" high net worth investors every day for fundraising for my biotech company. Most have less knowledge about pharmaceuticals than my special needs seven-year old son. These individuals would undoubtedly pass the proposed test, but they still won't have a clue.